FDMT4D Molecular Therapeutics, Inc.

$468M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$977,000-148.1% YoY

Gross Profit

-$14M1390.2% margin

Operating Income

-$20M2090.3% margin

Net Income

-$21M2103.1% margin

EPS (Diluted)

$-0.77

QoQ Revenue Growth

-113.2%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$288M

Total Liabilities

$32M

Stockholders' Equity

$256M

Cash & Equivalents

$277M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$977,000	$2M	-148.1%
Gross Profit	-$14M	-$10M	-31.5%
Operating Income	-$20M	-$16M	-25.4%
Net Income	-$21M	-$16M	-27.5%

FDMT Q4 2020 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena